Ranluspec is the only interchangeable ranibizumab biosimilar approved in the United States in both vial and pre-filled syringe (PFS) presentations
The industry is expected to grow significantly over the next few years as healthcare accessibility improves and insurance penetration increases
Regulatory clearance strengthens company’s global footprint and expands access to the Australian animal healthcare market
The approval is expected to support the company’s presence in regulated international markets and further strengthen its position as a reliable pharma manufacturing partner
We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals
Libre Duo devices become the first glucose-ketone monitors approved for diabetes care, offering real-time alerts for diabetic ketoacidosis risk
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
Dual regulatory clearances for Sentire(R) Endoscopic surgical system strengthen the company’s expansion across Europe and Asia-Pacific in minimally invasive robotic surgery
Approval of device in Australia for treating locally advanced pancreatic cancer alongside gemcitabine-based chemotherapy
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
